Primary mitochondrial myopathy: Clinical features and outcome measures in 118 cases from Italy.
Journal
Neurology. Genetics
ISSN: 2376-7839
Titre abrégé: Neurol Genet
Pays: United States
ID NLM: 101671068
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
04
05
2020
accepted:
04
08
2020
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
20
11
2020
Statut:
epublish
Résumé
To determine whether a set of functional tests, clinical scales, patient-reported questionnaires, and specific biomarkers can be considered reliable outcome measures in patients with primary mitochondrial myopathy (PMM), we analyzed a cohort of Italian patients. Baseline data were collected from 118 patients with PMM, followed by centers of the Italian network for mitochondrial diseases. We used the 6-Minute Walk Test (6MWT), Timed Up-and-Go Test (x3) (3TUG), Five-Times Sit-To-Stand Test (5XSST), Timed Water Swallow Test (TWST), and Test of Masticating and Swallowing Solids (TOMASS) as functional outcome measures; the Fatigue Severity Scale and West Haven-Yale Multidimensional Pain Inventory as patient-reported outcome measures; and FGF21, GDF15, lactate, and creatine kinase (CK) as biomarkers. A total of 118 PMM cases were included. Functional outcome measures (6MWT, 3TUG, 5XSST, TWST, and TOMASS) and biomarkers significantly differed from healthy reference values and controls. Moreover, functional measures correlated with patients' perceived fatigue and pain severity. Patients with either mitochondrial or nuclear DNA point mutations performed worse in functional measures than patients harboring single deletion, even if the latter had an earlier age at onset but similar disease duration. Both the biomarkers FGF21 and GDF15 were significantly higher in the patients compared with a matched control population; however, there was no relation with severity of disease. We characterized a large cohort of PMM by evaluating baseline mitochondrial biomarkers and functional scales that represent potential outcome measures to monitor the efficacy of treatment in clinical trials; these outcome measures will be further reinvestigated longitudinally to define the natural history of PMM.
Identifiants
pubmed: 33209982
doi: 10.1212/NXG.0000000000000519
pii: NG2020014191
pmc: PMC7670572
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e519Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Neuromuscul Disord. 2017 Dec;27(12):1126-1137
pubmed: 29074296
Neurology. 2018 Apr 3;90(14):e1212-e1221
pubmed: 29500292
Muscle Nerve. 2018 Jan;57(1):136-139
pubmed: 28545168
J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):199-201
pubmed: 17872980
Neurology. 2013 Nov 19;81(21):1819-26
pubmed: 24142477
Rev Pain. 2008 Dec;2(2):20-4
pubmed: 26526773
Curr Opin Neurol. 2014 Oct;27(5):576-82
pubmed: 25188013
Ann Neurol. 2015 Nov;78(5):814-23
pubmed: 26463265
Neurology. 2020 Feb 18;94(7):e687-e698
pubmed: 31896620
J Neurol Neurosurg Psychiatry. 1992 Sep;55(9):822-5
pubmed: 1402974
J Neurol. 2015 May;262(5):1301-9
pubmed: 25808502
Mitochondrion. 2017 Jan;32:27-30
pubmed: 27856367
EMBO Mol Med. 2018 Jun;10(6):
pubmed: 29735722
Muscle Nerve. 2008 Aug;38(2):964-71
pubmed: 18642379
Mitochondrion. 2019 Jan;44:15-19
pubmed: 29246868
Muscle Nerve. 2018 Apr;57(4):561-568
pubmed: 29280483
Neurology. 2016 Nov 29;87(22):2290-2299
pubmed: 27794108
N Engl J Med. 2010 Apr 15;362(15):1396-406
pubmed: 20393176
J Neurol. 2011 Nov;258(11):2020-5
pubmed: 21533826
Neuromuscul Disord. 2012 Dec;22 Suppl 3:S226-9
pubmed: 23182644
Eur J Neurol. 2010 Jun 1;17(6):767-73
pubmed: 20402744
Can J Neurol Sci. 2011 Jan;38(1):119-23
pubmed: 21156440
Muscle Nerve. 2013 Sep;48(3):343-56
pubmed: 23681930
Ann Neurol. 2019 Aug;86(2):293-303
pubmed: 31125140
Am Heart J. 2007 Oct;154(4):655-61
pubmed: 17892987
J Clin Med. 2017 Aug 21;6(8):
pubmed: 28825656
Int J Lang Commun Disord. 2018 Jan;53(1):144-156
pubmed: 28677236
Pain. 1985 Dec;23(4):345-56
pubmed: 4088697
Respir Med. 2006 Sep;100(9):1573-8
pubmed: 16466676
Nat Rev Dis Primers. 2016 Oct 20;2:16080
pubmed: 27775730
Percept Mot Skills. 2006 Aug;103(1):215-22
pubmed: 17037663